U.S. Luxury Stock News

If you are wondering whether nLIGHT's share price still reflects its underlying value, it helps to step back from the excitement and look closely at what the numbers actually say. The stock trades at US$53.98 after a 40.7% return year to date, which comes on top of a very large 1 year gain and a 438.7% return over 3 years, despite a recent 22.8% 7 day pullback and a modest 3.9% 30 day decline. Recent coverage has focused on nLIGHT's position in high performance laser technology and its role...

Earlier in March 2026, Casella Waste Systems, Inc. appointed Christopher A. Rains as Senior Vice President and Chief Revenue Officer, adding a leader with more than two decades of commercial, operational, and customer-focused experience across major waste management and industrial companies. Rains’ combination of industry depth, Lean Six Sigma Black Belt training, and proven work on complex organizational transformations introduces fresh commercial leadership that could influence how Casella...

Apogee Therapeutics recently reported positive 52-week Phase 2 APEX trial data for its lead anti-IL-13 antibody zumilokibart in moderate-to-severe atopic dermatitis, alongside completing a follow-on common stock offering of about US$403,000,000 at US$70 per share. The maintenance data suggest zumilokibart may offer durable disease control with 3- or 6-month dosing intervals, a dosing schedule that could meaningfully differentiate it from existing atopic dermatitis treatments if later-stage...

Middleby stock performance and recent context Middleby (MIDD) has been under pressure recently, with the share price showing negative returns over the past week, month and past 3 months, prompting investors to reassess how its current valuation lines up with the underlying business. See our latest analysis for Middleby. The recent 24.68% 30 day share price decline, alongside a 16.31% 1 year total shareholder return decline, suggests momentum has faded and investors are reassessing Middleby at...

In March 2026, Protagonist Therapeutics reported one-year Phase 3 data for ICOTYDE (icotrokinra) in moderate to severe plaque psoriasis, showing sustained skin clearance and a favorable safety profile as the first oral IL-23 receptor–targeted peptide. The data, including adolescent results through Week 52, underline ICOTYDE’s potential as a once-daily pill alternative to injectable treatments and highlight the company’s peptide discovery platform. We’ll now look at how ICOTYDE’s...

Event context and recent price performance Biglari Holdings (BH.A) recently caught investor attention after a 3% move in the latest session, contrasting with a decline of about 17% over the past month and a smaller pullback over the past 3 months. See our latest analysis for Biglari Holdings. That recent 3% daily share price move sits against a weaker short term trend, with a 30 day share price return of about a 17% decline. However, the 1 year total shareholder return of 50.73% and 5 year...

At the March 12, 2026 BofA Securities Information & Business Services Conference, First Advantage Corporation highlighted 17% fourth-quarter revenue growth, a transition toward capital risk management solutions, and board approval of a US$100,000,000 share repurchase program. The company’s emphasis on expanding beyond background screening into a broader capital risk management platform, supported by about 97% client retention, underlines management’s confidence in scaling the business...

Relay Therapeutics (RLAY) is back in focus after releasing new Phase 1/2 ReDiscover trial data for zovegalisib plus fulvestrant in PI3Ka-mutated, HR+/HER2- metastatic breast cancer, supporting its selected Phase 3 dosing regimen. See our latest analysis for Relay Therapeutics. The latest trial update comes after a sharp move in the stock, with a 1 day share price return of negative 5.14% and a 30 day share price return of negative 6.43%. However, a 1 year total shareholder return of 266.41%...

Recently, Globant and PharmaMar announced a collaboration to apply Globant Enterprise AI in accelerating cancer drug discovery, while Globant and Adyen formalized a global partnership making Globant a lead integration partner for Adyen’s payments platform. Together, these alliances show how Globant is embedding its AI and integration capabilities at the core of critical workflows in both healthcare R&D and global payments infrastructure. Now we’ll examine how Globant’s AI-powered PharmaMar...

With no single headline event driving Allegion (ALLE) into focus, investors are instead looking at the stock's recent performance and fundamentals, including its US$4,067.3m in revenue and US$643.8m in net income. See our latest analysis for Allegion. Allegion’s recent share price performance has been soft, with a 1-month share price return of 10.33% and a year to date share price return of 10.2%. The 1-year total shareholder return sits at 12.27%, which hints at longer term holders faring...

Schneider National (SNDR) recently reported quarterly results, with revenue up 4.5% year on year but below analyst expectations, and full-year EPS guidance also under forecasts. This combination has coincided with a 13.5% decline in the share price. See our latest analysis for Schneider National. At a share price of $25.44, Schneider National’s 30 day share price return of 10.36% and 90 day share price return of 5.25% sit against a 1 year total shareholder return of 13.07%. This indicates...

Global Partners (GLP) has drawn investor attention after its recent share moves, with the stock closing at US$44.37. That price appears alongside mixed recent returns and a value score of 3. See our latest analysis for Global Partners. The recent pullback, with a 1-day share price return of 1.40% decline and a 7-day share price return of 4.42% decline, contrasts with a 90-day share price return of 3.98% and multi year total shareholder returns that remain strongly positive. This points to...

Kennametal (KMT) is back on investors’ radar after its consensus EPS estimate for the current year moved 56.8% higher in the past 3 months, alongside an upgrade to Zacks Rank #1. See our latest analysis for Kennametal. The share price has moved to US$36.08 after a 25.93% 90 day share price return. The 1 year total shareholder return of 74.83% contrasts with a recent 10.43% 1 month share price decline, suggesting that momentum has cooled after a strong run. If this kind of swing in sentiment...

On March 23, Sensient Food Colors, a division of Sensient Technologies, marked the start of “Project Prism,” a major expansion of its largest natural color plant in St. Louis, Missouri, as part of a planned US$250 million program to grow capacity, supply chain and workforce. This expansion underlines how Sensient is committing significant long-term capital to meet rising demand for natural food colors as brands move away from artificial additives. Next, we’ll examine how Project Prism’s...

Arcellx (ACLX) has drawn attention after fresh performance data on its lead cancer immunotherapies prompted investors to reassess both the company’s clinical pipeline and its recent share price strength over the past 3 months. See our latest analysis for Arcellx. Over the past year Arcellx’s share price return of 80.88% year to date and 80.14% over 90 days, compared with a 74.65% one year total shareholder return and 290.09% three year total shareholder return, points to strong momentum...

What Gevo’s North Dakota expansion announcement means for the stock Gevo (GEVO) has attracted fresh attention after outlining plans to potentially add a second low carbon ethanol plant at its North Dakota site. This would more than double the current nameplate capacity. See our latest analysis for Gevo. The expansion news arrives after a strong run in the shares, with a 30 day share price return of 38.46% and a year to date share price return of 22.33%, while the 1 year total shareholder...

Calumet stock snapshot after recent performance Calumet (CLMT) has drawn fresh attention after a strong run, with the share price at $32.06 and total return figures showing double digit gains over the past month and the past 3 months. See our latest analysis for Calumet. The recent 4.12% 1 day and 14.26% 7 day share price returns build on a strong run that includes a 62.49% 90 day gain and a 152.84% 1 year total shareholder return. This points to strong positive momentum rather than a short...

Oshkosh (OSK) is back in focus after its latest update, where revenue came in ahead of market expectations but full-year EPS guidance fell short, sending mixed signals for investors. See our latest analysis for Oshkosh. The share price has eased back recently, with a 1 day share price return of a 2.07% decline and a 1 month share price return of a 17.47% decline. This comes even though the 1 year total shareholder return is 51.57% and the 3 year total shareholder return is 77.74%, suggesting...

Universal Health Services share performance and recent context Universal Health Services (UHS) has drawn attention after a period of weaker share performance, with the stock showing a return of about negative 18% over the past 3 months and negative 11% over the past month. For investors tracking longer horizons, UHS shows a negative year to date return of roughly 16% and a modest negative total return over the past year, while the 3 year and 5 year total returns remain positive. See our...

In March 2026, Pulse Biosciences, Inc. announced a new focus on accelerating development and future commercialization of its nPulse Cardiac Catheter Ablation System after reporting European feasibility data in Atrial Fibrillation showing high procedural success, durable Pulmonary Vein Isolation, efficient procedure times, and a low rate of serious adverse events. This shift in capital allocation toward the electrophysiology program, alongside streamlined spending in surgical and soft-tissue...

MeiraGTx Holdings plc ( NASDAQ:MGTX ) just released its latest annual results and things are looking bullish. The...

Why Darling Ingredients Is Back on Investors’ Radar Recent gains in Darling Ingredients (DAR) have pushed the stock higher over the past month and past 3 months, drawing attention to how its feed, food, and fuel ingredients businesses are contributing to current performance. See our latest analysis for Darling Ingredients. The recent momentum in Darling Ingredients stands out, with a 30-day share price return of 11.51%, a 90-day share price return of 62.28%, and a 1-year total shareholder...

Soft earnings didn't appear to concern Star Bulk Carriers Corp.'s ( NASDAQ:SBLK ) shareholders over the last week. We...

In April 2026, W. R. Berkley reported its fiscal Q1 results, with analysts having anticipated earnings of US$1.14 per share, implying 12.9% year-on-year growth and building on a recent pattern of meeting or beating expectations in three of the last four quarters. This track record of earnings delivery, combined with analyst projections for continued EPS expansion in coming years, has become a key focus for investors watching how consistently the insurer can convert its specialty underwriting...